Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) traded at a new 52-week high today of $1.86. This new high was reached on below average trading volume as 100,000 shares traded hands, while the average 30-day volume is approximately 19.1 million shares.
Tonix Pharmaceuticals Holding Corp. share prices have moved between a 52-week high of $1.86 and a 52-week low of $0.15 and are now trading 1,100% above that low price at $1.80 per share.
Tonix Pharmaceuticals Holding Corp is a clinical-stage pharmaceutical company. The company is engaged in discovering, licensing, acquiring and developing drugs and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes biologics to prevent infectious diseases and small molecules and biologics to treat pain, psychiatric and addiction conditions. While the company is also developing a potential vaccine to protect against the novel coronavirus disease.
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) defies analysts with a current price ($1.80) 70.8% above its average consensus price target of $0.52.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com